(Q34135229)

31 July 2017

1 reference

title

The management of superficial bladder cancer. (English)

1 reference

31 July 2017

Oosterlinck W

1

1 reference

31 July 2017

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

87

1 reference

31 July 2017

2

1 reference

31 July 2017

135-140

1 reference

Urine cytology. It is still the gold standard for screening?

31 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

Multivariate analysis of the prognostic factors of primary superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

Long-term survival of patients with bladder tumours: the significance of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

Factors affecting recurrence and progression in superficial bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

Low-dose bacille Calmette-Guérin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

The treated natural history of high risk superficial bladder cancer: 15-year outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

Megadose vitamins in bladder cancer: a double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

The role of photodynamic therapy in the treatment of recurrent superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00948.X

10.1046/J.1464-410X.2001.00948.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11167630